Whether to drop a secondary endpoint that will dominate the AdCom from RWE

Situation

In a safety team sitting on a new disproportionate signal, RWE protocol that may not meet regulator expectations is the evidence after an inspector asking for batch records you cannot produce this week. Pharmacovigilance medical reviewer has to pick Proceed under protocol or Pause the pathway for this Pharma & Life Sciences FDA Response and Labeling close using RWE protocol that may not meet regulator expectations.

Decision

Pharmacovigilance medical reviewer in a safety team sitting on a new disproportionate signal must choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold using RWE protocol that may not meet regulator expectations after an inspector asking for batch records you cannot produce this week.

Hypotheses to test

• An inspector asking for batch records you cannot produce this week is noise around an already-controlled FDA Response and Labeling process in a safety team sitting on a new disproportionate signal, given RWE protocol that may not meet regulator expectations.
• An inspector asking for batch records you cannot produce this week is the event in RWE protocol that may not meet regulator expectations that forces Proceed under protocol for pharmacovigilance medical reviewer under Pharma & Life Sciences.
• RWE protocol that may not meet regulator expectations shows a one-file miss after an inspector asking for batch records you cannot produce this week, not a FDA Response and Labeling program failure.
• RWE protocol that may not meet regulator expectations cannot decide to drop a secondary yet after an inspector asking for batch records you cannot produce this week; hold is the only Pharma & Life Sciences close a safety team sitting on a new disproportionate signal can defend.

Analysis required

• Map FDA-response timing and owner in a safety team sitting on a new disproportionate signal.
• Trace CMC, labeling, or pharmacovigilance facts in RWE protocol that may not meet regulator expectations after an inspector asking for batch records you cannot produce this week.
• Separate an isolated adverse event from a systemic quality issue.
• For this Pharma & Life Sciences FDA Response and Labeling file, read RWE protocol that may not meet regulator expectations against an inspector asking for batch records you cannot produce this week and write the one fact that would move to drop a secondary for pharmacovigilance medical reviewer.